The chemotherapeutic galvanostat/potentiostat (CGP) is a  patent protected invention in the United States of America and Canada, with patent cooperation treaty (PCT) disclosure, effectively making the CGP and it's underlying technologies hereby unpatentable in every country on Earth, post 2017 (figure 1).

​

​​

​

​

​

​

​

​

​

​

​Figure 1. The World of Innovative Potential. White: Patent Zone; Green: Disclosure Zone.

Expiry: 2038

​

Figure 1 has four (4) essential implications and effects, namely:
 

1. Individuals, public governments, and companies in unpatented nations do not have: the ability to gain domestic patent protection for CGP production, processes, and or use because of previous disclosure (i.e.: it's not inventable by you because it was already invented by me; and, that publication, or disclosure, is now Nationally and legally recognized across all PCT-member Nations); which means:
    

2. The legal duties and responsibilities for local-nation CGP technology, knowledge, application, and preservation are legally bound to those entities entreatied by the PCT, and  do not have National patents issued; additionally: those entities can not monopolize CGP technology within their nations; and,
    

3. Those entities that do have national patents issued (i.e.: The United States, and Canada) are bound to Innovative Potential as a type of centralized government for the purposes of the patent (i.e.: these two (2) governments are internally and legally obligated to participate with Innovative Potential at the exclusion of all others, and their lives depend on it, failure to participate directly results in The Situation); and,
    

4. The entire Disclosure Zone is one gigantic free market, but not the Patent Zone: the Patent Zone is a regulated or controlled market (i.e.: monopolized; i.e.: Innovative Potential).

​​